The reaction was the problem, and the gene was the answer. Before testing, 5% to 8% of European-descent patients on abacavir got a high fever, a body-wide rash, and GI symptoms in their first two weeks. Almost every one of them carried HLA-B*57:01. Screen for the variant and steer carriers to another drug, and confirmed reactions drop from 2.7% of patients to zero 1. The marker holds equally in Black and white patients 2.
The variant is not a risk factor, it's a switch. Abacavir slips into a pocket on the HLA-B*57:01 protein and nowhere else, changing which bits of your own cells the immune system displays; it reads the new set as foreign and attacks 3. No variant, no pocket, no reaction.
This is a decision, not a routine. The only action is to make sure the test happens before the drug does.
For most people, nothing visible happens. A negative result files itself into your record and abacavir starts. For carriers, the morning the result comes back positive is the morning a different drug gets prescribed and a reaction that would have hit you never does. At the population scale, a whole category of severe drug reaction stopped happening in HIV clinics. And the test wrote a playbook: screening for DPYD before chemotherapy, HLA-B*58:01 before allopurinol, HLA-B*15:02 before carbamazepine all follow the arc this one ran first.
Cash price runs $50 to $200, but almost nobody pays it: insurance, Medicaid, Ryan White, the NHS, and most public payers cover it, because one hypersensitivity hospitalization costs far more than screening everyone 5. Everyone gets tested regardless of ancestry — self-reported ancestry is unreliable and guessing wrong is expensive 6.
The fine print — when to skip it, and what people get wrong
A negative test doesn't clear every early fever or rash; non-carriers still get unrelated illnesses, and clinicians still pause the drug if the picture is unclear. And it's not "just a rash" — it's a whole-body hypersensitivity reaction.
The lethal case is re-challenge: a carrier mistakes the reaction for a stomach bug, stops, restarts, and blood pressure crashes within hours. That drove abacavir's boxed warning 4; a single dose in a confirmed carrier is never given.
- 1Mallal et al. (2008). HLA-B*5701 screening for hypersensitivity to abacavir (PREDICT-1). New England Journal of Medicine. link
- 2Saag et al. (2008). High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients (SHAPE). Clinical Infectious Diseases. link
- 3Illing et al. (2012). Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature. link
- 4FDA (2008). FDA labeling change for abacavir: HLA-B*5701 screening recommended prior to initiation. link
- 5Schackman et al. (2008). The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS. link
- 6Martin et al. (2014). Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and abacavir dosing: 2014 update. Clinical Pharmacology & Therapeutics. link
დაკავშირებული სახელმძღვანელოში (4)
- — Like HLA-B*57:01, G6PD status is a one-time genetic check that flags drugs to avoid.
- — HLA-B*57:01 is a clear instance of genetic testing actually altering what you're prescribed.
- — Like HLA-B*57:01 before abacavir, HLA-B27 is a one-and-done HLA test for a specific question.
- — The abacavir gene test is the textbook pharmacogenomic win — one gene checked before one drug.
HLA-B*57:01 Testing Before Abacavir
Cash price approximately $50–$200 in the U.S.; covered by insurance, Medicaid/Medicare, the Ryan White program, and essentially all national health systems globally. Cost-effective by standard willingness-to-pay thresholds (Schackman et al., AIDS 2008).
One-time blood draw or buccal swab ordered as part of routine HIV care. Result returns in 1–7 days and is valid for life — HLA genotype does not change.
Mechanism characterized at molecular level (Illing et al., Nature 2012). Prospective RCT in 1,956 patients showing complete elimination of immunologically confirmed HSR (Mallal et al., NEJM 2008). Multi-ethnic confirmation in SHAPE (Saag et al., CID 2008). FDA boxed warning (2008), CPIC guideline (Martin et al., CPT 2014), and DHHS antiretroviral guidelines all uniformly require pre-prescription screening.
For carriers prescribed abacavir, the test prevents a systemic delayed hypersensitivity reaction (fever, rash, GI, respiratory involvement) that develops within 11 days in roughly 50–60% of HLA-B*57:01-positive patients. PREDICT-1 showed prospective screening eliminated immunologically confirmed HSR (0% vs 2.7% in the unscreened arm) (Mallal et al., NEJM 2008).
Re-exposure to abacavir after an unrecognized HSR can cause a fatal hypotensive crisis; pre-screening era fatalities drove the regulatory response. Screening eliminates this mortality risk for the ~5–8% of European-descent (and variable by ancestry) carriers who would otherwise receive abacavir. Population-level effect is small but the individual-level effect is large.